FDA Antiviral Advisory Committee April 28, 2011 meeting background materials available: telaprevir for Hepatitis C

Background materials for the April 28 FDA Antiviral Advisory Committee meeting to discuss telaprevir, a direct acting antiviral (DAA) intended for the treatment of hepatitis C are available on the FDA web site through the following links...

• April 28, 2011: Antiviral Drugs Advisory Committee Meeting Announcement
• Draft Agenda for the April 28, 2011 Meeting of the Antiviral Drugs Advisory Committee (PDF - 85KB)
• Draft Questions for the April 28, 2011 Meeting of the Antiviral Drugs Advisory Committee (PDF - 21KB)
• Draft Meeting Roster for the April 28, 2011 Meeting of the Antiviral Drugs Advisory Committee (PDF - 102KB)
• Committee Roster for the April 28, 2011 Meeting of the Antiviral Drugs Advisory Committee (PDF - 25KB)
• Webcast Information for the April 28, 2011 Meeting of the Antiviral Drugs Advisory Committee (PDF - 16KB)
• Briefing Information for the April 28, 2011 Meeting of the Antiviral Drugs Advisory Committee

Richard Klein
Office of Special Health Issues
Food and Drug Administration

Kimberly Struble
Division of Antiviral Drug Products
Food and Drug Administration